114亿美元，新纪录！

Core Insights - A significant global strategic collaboration has been established between Innovent Biologics and Takeda Pharmaceutical, with a total transaction value potentially reaching $11.4 billion [1][3]. Group 1: Collaboration Details - The partnership focuses on the global development of Innovent's next-generation IO and ADC therapies, specifically IBI363 (PD-1/IL-2-bias), IBI343 (CLDN18.2 ADC), and an early-stage project IBI3001 (EGFR/B7H3 ADC) [2][3]. - Innovent will receive an upfront payment of $1.2 billion, which includes a strategic equity investment of $100 million at a 20% premium to the weighted average closing price over the previous 30 trading days [3]. - The collaboration includes milestone payments that could total up to $10.2 billion, making the overall deal potentially worth $11.4 billion [3]. Group 2: Market Impact - Following the announcement, Innovent's stock price surged by 6.5%, bringing its market capitalization to HKD 158.9 billion [2]. - The partnership is expected to enhance Innovent's global strategy and expand its market presence, particularly in the oncology sector [3][4]. - Takeda's global oncology division anticipates that IBI363 and IBI343 will address critical gaps in the treatment of various solid tumors, potentially leading to significant breakthroughs in their oncology pipeline [4].